This document was published more than 2 years ago. The nature of the evidence may have changed.
Restless legs syndrome (RLS) is a neurological disorder associated with uncomfortable and occasionally painful creeping sensations in the legs and/or arms. Restless legs syndrome can be categorized as primary or secondary, depending on the onset mechanism. Dopaminergic agents, which include dopamine agonists1 and levodopa, are used to ameliorate the symptoms of RLS.
The most common symptom in RLS is creeping sensations (paresthesias) affecting the lower legs. The symptoms usually appear during rest, in the evening, and at night, causing a strong urge to move the affected part of the body to relieve the symptoms.
A genetic association is suspected in primary RLS, and several genes with a probable association to RLS have been identified. The secondary form of the disorder is probably caused by another underlying disease, or a deficiency in certain vitamins or minerals.
The prevalence of RLS, including all forms of the disorder, is estimated at 5% to 10% of the adult population in Europe and North America. An estimated one fourth of people with RLS have symptoms severe enough to require medication. This corresponds to approximately 200 000 individuals in Sweden. Twice as many women as men are affected, and the disorder is more common in older people than in younger people.
The causes of RLS remain largely unknown. Research suggests that the condition could be partly attributed to the malfunction of certain dopamine-releasing parts of the central nervous system, which could possibly disrupt movement functions in the body, thereby causing the symptoms. The dopaminergic activity can be amplified with dopamine-receptor-activating drugs (dopamine agonists) or levodopa.
Depending on their chemical structure, dopamine agonists can be divided into two different pharmacological groups: ergot-derived and nonergot-derived. Three nonergot dopamine agonists – pramipexole, ropinirole, and rotigotine – are currently approved in Sweden for treating RLS. Treatment involving dopamine agonists aims to ameliorate disease symptoms and is used mainly for patients with moderate to severe primary RLS. Levodopa is also used for milder discomfort and in secondary RLS. Levodopa, however, is not registered in Sweden as a treatment for RLS.
Dopamine agonists relieve symptoms2 in patients with moderate to severe primary RLS (Evidence Grade 1)*. The effect is moderate in comparison to placebo, and most studies have not followed patients for more than 3 months. Treatment with dopamine agonists also results in increased sleep time and improved sleep quality and leads to improving quality of life (Evidence Grade 2)*. Dopamine agonists, however, have side effects that have caused some patients to terminate their participation in studies prematurely. Evidence concerning the longer-term side effects of RLS is limited.
SBU bases its assessment on 10 randomized controlled trials (RCTs) involving the use of dopamine agonists to treat moderate to severe primary RLS. Of these RCTs, 3 involved pramipexole, 4 involved ropinirole, 2 involved rotigotine, and 1 involved cabergoline. The first three drugs are nonergot dopamine agonists, while the fourth is ergot-derived. In total, the studies included nearly 4000 patients.
A meta-analysis shows that average symptom relief was just over 50% after treatment with nonergot dopamine agonists and 35% after placebo treatment. The studies also show that treatment with these drugs improves sleep and quality of life and reduces daytime tiredness.
Overall, the rate of side effects in the studies averaged 75% in the treatment groups and 63% in the placebo groups. The side effects were usually mild to moderate, but severe side effects were also reported. Patients who received active treatment had a greater tendency to terminate a study prematurely due to adverse effects (on average 12% in the treatment groups and 7% in the placebo groups).
Observation times in the studies are relatively short, and few studies report more than 3 months of follow up. Hence, knowledge is limited regarding the drugs’ longer-term effects on RLS and the risk for delayed side effects. Due to the risks for cardiac-related side effects, particular caution should be exercised in using ergot agonists.
The findings suggest that the three dopamine agonists, ie, pramipexole, ropinirole, and rotigotine, have similar effects in terms of symptom relief and side effects. However, studies that compare these drugs with each other are lacking.
Compared to placebo, treatment with levodopa reduces periodic limb movements during sleep in patients with primary or secondary RLS (Evidence Grade 3)*. Treatment with levodopa also has positive effects on patients’ sleep and quality of life (Evidence Grade 3)*. Scientific evidence is insufficient* to draw conclusions on the side effects of levodopa.
Four randomized, placebo-controlled trials of levodopa treatment have been included in the assessment. All of these studies appeared in older publications (1988–1999) and mainly assessed the surrogate endpoint of periodic limb movements (PLM) during sleep. In addition to patients with primary RLS, the studies also included patients with secondary forms of the disorder.
The results suggest that the number of PLM per hour decreases with levodopa treatment compared to placebo. However, the relevance of the effects is difficult to judge since baseline values were reported in only one of the studies. Further, the results suggest that levodopa treatment has positive effects on patients’ sleep and quality of life. The scientific evidence is insufficient to assess the effects of levodopa treatment on patient-assessed sensory symptoms (creeping sensations).
Further studies are essential to establish the effectiveness, and the side effects, of levodopa in treating RLS.
Knowledge is limited about potential, delayed side effects of dopaminergic agents in treating RLS. Few treatment options are currently available for patients with more severe RLS, and dopaminergic agents usually comprise first-line treatment. However, there is a risk of widening treatment indications (ie, prescribing dopamine agonists to patients with milder symptoms, where the disorder is not associated with long-term complications or increasing morbidity). From an ethical standpoint it is important that patients who have the greatest need for pharmacotherapy have access to this treatment.
Scientific evidence is insufficient* to draw conclusions on the cost-effectiveness of dopaminergic agents.
The cost of regular treatment with dopamine agonists can be estimated at 3000 to 4000 Swedish kronor (SEK) per patient and year. Calculated per patient responding to treatment, the cost is substantially higher and is estimated at SEK 25 000 to SEK 40 000, depending on how response is defined. The cost of treatment with levodopa can be estimated at SEK 500 to SEK 1500 per patient and year, depending on the dose and regularity of treatment. This estimate, however, does not account for those who respond to treatment.
* Criteria for Evidence Grading SBU’s Conclusions
Evidence Grade 1 – Strong Scientific Evidence. The conclusion is corroborated by at least two independent studies with high quality, or a good systematic overview.
Evidence Grade 2 – Moderately Strong Scientific Evidence. The conclusion is corroborated by one study with high quality, and at least two studies with medium quality.
Evidence Grade 3 – Limited Scientific Evidence. The conclusion is corroborated by at least two studies with medium quality.
Insufficient Scientific Evidence – No conclusions can be drawn when there are not any studies that meet the criteria for quality.
Contradictory Scientific Evidence – No conclusions can be drawn when there are studies with the same quality whose findings contradict each other.
This summary is based on a report prepared by SBU in collaboration with Björn Holmberg, MD, PhD, Sahlgrenska University Hospital, Gothenburg and Håkan Widner, MD, Professor, Lund University Hospital, Lund. It has been reviewed by Björn Arvidson, MD, Associate Professor, Medical Products Agency, Uppsala and Peter Mattsson, MD, Associate Professor, Uppsala University Hospital, Uppsala. Project manager: Johan Wallin, SBU.
The complete report is available in Swedish.
SBU Alert is a service provided by SBU in collaboration with the Medical Products Agency, the National Board of Health and Welfare, and the Swedish Association of Local Authorities and Regions.
The estimated size of the target group has been revised since publication of this report.
presents a comprehensive, systematic assessment of available scientific evidence. The certainty of the evidence for each finding is systematically reviewed and graded. Full assessments include economic, social, and ethical impact analyses.
SBU assessments are performed by a team of leading professional practitioners and academics, patient/user representatives and SBU staff. Prior to approval and publication, assessments are reviewed by independent experts, SBU’s Scientific Advisory Committees and Board of Directors.